1. Transplantation, bridging, and support technologies in pulmonary hypertension.
- Author
-
Savale L, Benazzo A, Corris P, Keshavjee S, Levine DJ, Mercier O, Davis RD, and Granton JT
- Subjects
- Humans, Risk Assessment, Heart-Assist Devices, Ventricular Dysfunction, Right therapy, Ventricular Dysfunction, Right physiopathology, Pulmonary Edema therapy, Primary Graft Dysfunction therapy, Hypertension, Pulmonary therapy, Lung Transplantation
- Abstract
Despite the progress made in medical therapies for treating pulmonary hypertension (PH), a subset of patients remain susceptible to developing a maladaptive right ventricular phenotype. The effective management of end-stage PH presents substantial challenges, necessitating a multidisciplinary approach and early identification of patients prone to acute decompensation. Identifying potential transplant candidates and assessing the feasibility of such a procedure are pivotal tasks that should be undertaken early in the treatment algorithm. Inclusion on the transplant list is contingent upon a comprehensive risk assessment, also considering the specific type of PH and various factors affecting waiting times, all of which should inform the decision-making process. While bilateral lung transplantation is the preferred option, it demands expert intra- and post-operative management to mitigate the heightened risks of pulmonary oedema and primary graft dysfunction in PH patients. Despite the availability of risk assessment tools, the occurrence of acute PH decompensation episodes can be unpredictable, potentially leading to refractory right ventricular failure even with optimal medical intervention, necessitating the use of rescue therapies. Advancements in right ventricular assist techniques and adjustments to graft allocation protocols for the most critically ill patients have significantly enhanced the survival in intensive care, affording the opportunity to endure while awaiting an urgent transplant. Given the breadth of therapeutic options available, specialised centres capable of delivering comprehensive care have become indispensable for optimising patient outcomes. These centres are instrumental in providing holistic support and management tailored to the complex needs of PH patients, ultimately enhancing their chances of a successful transplant and improved long-term prognosis., Competing Interests: Conflict of interest: L. Savale reports grants from Acceleron, Janssen and Merck MSD, and payment or honoraria for lectures, presentations, manuscript writing or educational events from Bayer, Janssen and Merck MSD. A. Benazzo reports grants from XVIVO Perfusion. P. Corris reports participation on a data safety monitoring board or advisory board with MSD and Gossamer. R.D. Davis reports support for attending meetings from WSPHA, and participation on a data safety monitoring board or advisory board with Transmedics Lung EVLP registry. J.T. Granton reports grants from Bayer, Janssen Pharmaceuticals, United Therapeutics, Acceleron, Merck and AstraZeneca, consultancy fees from Merck, and payment or honoraria for lectures, presentations, manuscript writing or educational events from AstraZeneca. The remaining authors have no potential conflicts of interest to disclose., (Copyright ©The authors 2024.)
- Published
- 2024
- Full Text
- View/download PDF